2 results
Approved WMOCompleted
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Approved WMORecruiting
Overall program:The overall aim of this project is to improve the outcome of patients diagnosed with ependymoma by improving the staging and the standard of care and to improve our understanding of the underlying biology. The program will evaluate…